A 75-year-old man, who previously underwent bilateral orchiectomy due to uncontrolled raise of prostate-specific antigen (PSA) was treated with 3 courses of Taxotere chemotherapy for prostate cancer. Bone scintigra phy revealed multiple metastatic lesions in the skull, spine, ribs, left iliac wing, and both humeri. He was admitted to the Oncology Institute with a complaint of dizziness, double vision, malaise, trismus like symptoms and thrombocytopenia. Enhanced magnetic resonance imaging (MRI) of the brain demonstrated diffusely thickened and enhancing dura at the convexity of the brain. No enhancing lesions were seen in the brain parenchyma. Additionally, diffusely decreased T1-weighted signal was demonstrated in the skull bones, clivus, and cervical spine, without mass effect, characteristic for metastatic disease. Brain metastases are rare in prostate cancer and occur late in the course of the disease (1). They usually represent the failure of hormonedeprivation therapy and the presence of disseminated disease. The leptomeninges are the most common intracranial sites of prostate cancer metastasis (67%) followed by cerebrum (25%), and cerebellum (8%) (1). Literature data showed that the average time from the diagnosis of prostate cancer to the occurrence of cerebral or meningeal metastatic disease is 60 months (2). Metastasis to the brain can occur by way of Batson's plexus or by direct extension from adjacent structures such as the sphenoid bone or sinuses (3).
{"title":"MRI of the carcinomatous meningitis - rare form of prostate cancer dissemination","authors":"R. Semnic, M. Semnic, D. Kozic","doi":"10.2298/AOO1302077S","DOIUrl":"https://doi.org/10.2298/AOO1302077S","url":null,"abstract":"A 75-year-old man, who previously underwent bilateral orchiectomy due to uncontrolled raise of prostate-specific antigen (PSA) was treated with 3 courses of Taxotere chemotherapy for prostate cancer. Bone scintigra phy revealed multiple metastatic lesions in the skull, spine, ribs, left iliac wing, and both humeri. He was admitted to the Oncology Institute with a complaint of dizziness, double vision, malaise, trismus like symptoms and thrombocytopenia. Enhanced magnetic resonance imaging (MRI) of the brain demonstrated diffusely thickened and enhancing dura at the convexity of the brain. No enhancing lesions were seen in the brain parenchyma. Additionally, diffusely decreased T1-weighted signal was demonstrated in the skull bones, clivus, and cervical spine, without mass effect, characteristic for metastatic disease. Brain metastases are rare in prostate cancer and occur late in the course of the disease (1). They usually represent the failure of hormonedeprivation therapy and the presence of disseminated disease. The leptomeninges are the most common intracranial sites of prostate cancer metastasis (67%) followed by cerebrum (25%), and cerebellum (8%) (1). Literature data showed that the average time from the diagnosis of prostate cancer to the occurrence of cerebral or meningeal metastatic disease is 60 months (2). Metastasis to the brain can occur by way of Batson's plexus or by direct extension from adjacent structures such as the sphenoid bone or sinuses (3).","PeriodicalId":35645,"journal":{"name":"Archive of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2298/AOO1302077S","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68402537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Time trends of cancer incidence for all primary sites in the province of Vojvodina from 1985 to 2010","authors":"M. Miladinov-Mikov, T. Dugandžija","doi":"10.2298/aoo1304172m","DOIUrl":"https://doi.org/10.2298/aoo1304172m","url":null,"abstract":"","PeriodicalId":35645,"journal":{"name":"Archive of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68402261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Snežana Božanić, N. Šolajić, M. Milić, T. Petrovic
{"title":"Large tumor forming Pseudoangiomatous stromal hyperplasia of the breast: A case report","authors":"Snežana Božanić, N. Šolajić, M. Milić, T. Petrovic","doi":"10.2298/aoo1304131b","DOIUrl":"https://doi.org/10.2298/aoo1304131b","url":null,"abstract":"","PeriodicalId":35645,"journal":{"name":"Archive of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68402423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
L. Antic, D. Vukovic, Bosiljka Ðikanovic, D. Antić, S. Jankovic, T. Naumović
{"title":"Implementation of secondary preventive practice important for cervical cancer among women who use oral contraception","authors":"L. Antic, D. Vukovic, Bosiljka Ðikanovic, D. Antić, S. Jankovic, T. Naumović","doi":"10.2298/aoo1304091a","DOIUrl":"https://doi.org/10.2298/aoo1304091a","url":null,"abstract":"","PeriodicalId":35645,"journal":{"name":"Archive of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68402099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The authors of this paper presented the key moments in the development of proctology, a medical discipline which is an integral part of surgery, whose development path was inseparable from the historical development of operational medicine. Even in the ancient Egypt, proctology was an important branch of medicine. Out of eight of so far known medical papyri in the history of proctology, the most important one is the Beatty`s (Chester Beatty) papyrus from the 13th century BC, which is actually a short monograph on diseases of the anus and their treatment. In the ancient period, operative proctology reached the highest level in the time of Hippocrates. In detail, and with special care, the operative procedures of the large intestine, primarily perianal fistula and hemorrhoids were described in the Hippocratic writings. One of the most famous Roman medical writers, Celsus (Cornelius Celsus Asullus) described the surgery of hemorrhoids by their ligature and the surgery of anorectal fistula in two ways: ligation of the fistula channel by string of raw flax and fistula incision through the probe placed through the fistula channel. Doctors of the 18th and the 19th century introduced into practice some more complicated surgical procedures in the treatment of anorectal diseases. The French surgeons were the leaders. In 1710, Littre performed, for the first time, anus praeter naturalis and Jacques Lisfranc (1790-1847) pioneered the method of perineal resection of the rectum for cancer. The first rectoscope was constructed in 1895 and in 1903 it was introduced into practice by Kelly (Kelly Howard Atwood). A sudden progress in the diagnosis and treatment of anorectal diseases occurred after the Second World War and the trend has continued to this day.
{"title":"From history of proctology","authors":"J. Maksimovic, M. Maksimović","doi":"10.2298/AOO1301028M","DOIUrl":"https://doi.org/10.2298/AOO1301028M","url":null,"abstract":"The authors of this paper presented the key moments in the development of proctology, a medical discipline which is an integral part of surgery, whose development path was inseparable from the historical development of operational medicine. Even in the ancient Egypt, proctology was an important branch of medicine. Out of eight of so far known medical papyri in the history of proctology, the most important one is the Beatty`s (Chester Beatty) papyrus from the 13th century BC, which is actually a short monograph on diseases of the anus and their treatment. In the ancient period, operative proctology reached the highest level in the time of Hippocrates. In detail, and with special care, the operative procedures of the large intestine, primarily perianal fistula and hemorrhoids were described in the Hippocratic writings. One of the most famous Roman medical writers, Celsus (Cornelius Celsus Asullus) described the surgery of hemorrhoids by their ligature and the surgery of anorectal fistula in two ways: ligation of the fistula channel by string of raw flax and fistula incision through the probe placed through the fistula channel. Doctors of the 18th and the 19th century introduced into practice some more complicated surgical procedures in the treatment of anorectal diseases. The French surgeons were the leaders. In 1710, Littre performed, for the first time, anus praeter naturalis and Jacques Lisfranc (1790-1847) pioneered the method of perineal resection of the rectum for cancer. The first rectoscope was constructed in 1895 and in 1903 it was introduced into practice by Kelly (Kelly Howard Atwood). A sudden progress in the diagnosis and treatment of anorectal diseases occurred after the Second World War and the trend has continued to this day.","PeriodicalId":35645,"journal":{"name":"Archive of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2298/AOO1301028M","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68401839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nikola Jojić, V. Kojić, D. Kojić, K. Stankov, G. Bogdanovic
Background: Single-walled carbon nanotubes (SWCNTs) have been reported to induce cytotoxicity in different cell lines. Although the mechanisms underlying cytotoxicity are not fully understood, accumulation of reactive oxygen species (ROS) and oxidative damage is considered to be a likely contributing factor. Methods: Human lung carcinoma cells, A549, and human fetal lung fibroblasts, MRC-5 were used to assess the cytotoxicity of SWCNT in the presence and absence of a redox status regulator, N-acetylcysteine (NAC), via the MTT assay. Results: SWCNT induced a nearly three-fold greater loss of viability in A594 vs. MRC-5 cells at ≤250 μg/ml. SWCNT cytotoxicity at higher concentrations was similar for both cell lines, while NAC alone was non-toxic. The cytotoxicity of SWCNT (250 μg/ml) in combination with NAC to A549 cells was significantly decreased at the lowest NAC concentration (1.5 µg/ml), and was similar to NAC treatment alone at that concentration. Higher concentrations of NAC in combination with SWCNT (250 μg/ml) resulted in increased cytotoxicity in both A549 and MRC-5 cells. Conclusion: A549 malignant lung cells are more susceptible to low concentrations of SWCNT vs. normal lung cells, and low concentrations of N-acetylcysteine appear to be cytoprotective, possibly due to its antioxidant properties. [Projekat Ministarstva nauke Republike Srbije, br. 173014: Molecular mechanisms of redoxsignaling in homeostasis: Adaptation and pathology]
{"title":"Cytotoxicity of single-walled carbon nanotubes to human lung carcinoma cells: The influence of N-acetylcysteine","authors":"Nikola Jojić, V. Kojić, D. Kojić, K. Stankov, G. Bogdanovic","doi":"10.2298/AOO1302059J","DOIUrl":"https://doi.org/10.2298/AOO1302059J","url":null,"abstract":"Background: Single-walled carbon nanotubes (SWCNTs) have been reported to induce cytotoxicity in different cell lines. Although the mechanisms underlying cytotoxicity are not fully understood, accumulation of reactive oxygen species (ROS) and oxidative damage is considered to be a likely contributing factor. Methods: Human lung carcinoma cells, A549, and human fetal lung fibroblasts, MRC-5 were used to assess the cytotoxicity of SWCNT in the presence and absence of a redox status regulator, N-acetylcysteine (NAC), via the MTT assay. Results: SWCNT induced a nearly three-fold greater loss of viability in A594 vs. MRC-5 cells at ≤250 μg/ml. SWCNT cytotoxicity at higher concentrations was similar for both cell lines, while NAC alone was non-toxic. The cytotoxicity of SWCNT (250 μg/ml) in combination with NAC to A549 cells was significantly decreased at the lowest NAC concentration (1.5 µg/ml), and was similar to NAC treatment alone at that concentration. Higher concentrations of NAC in combination with SWCNT (250 μg/ml) resulted in increased cytotoxicity in both A549 and MRC-5 cells. Conclusion: A549 malignant lung cells are more susceptible to low concentrations of SWCNT vs. normal lung cells, and low concentrations of N-acetylcysteine appear to be cytoprotective, possibly due to its antioxidant properties. [Projekat Ministarstva nauke Republike Srbije, br. 173014: Molecular mechanisms of redoxsignaling in homeostasis: Adaptation and pathology]","PeriodicalId":35645,"journal":{"name":"Archive of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2298/AOO1302059J","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68401919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Gorana Matovina-Brko, Maja Ružić, M. Fabri, L. Popović, Ivana Kolarov-Bjelobrk, J. Trifunović
The natural course of hepatitis B virus (HBV) infection depends on the immune status of the host. In cancer patients, as the consequence of immune suppression due to chemotherapy and malignant disease itself, the balance between replicative potential of the virus and immune response of the host is disrupted leading to acute HBV infection or reactivation. We present a case of HBsAg positive, diffuse large B cell gastric lymphoma patient CD20+ staged IB, treated with six cycles of R-CHOP protocol and two cycles with rituximab monotherapy. Five months after the successful anticancer treatment, patient developed reactivation of chronic HBV infection (ten-fold increase in liver enzymes, HBsAg+, IgM antiHBc+, HBeAg(-), and HBV DNA 5×10 copies/ml). Antiviral therapy with lamivudine was started. Four weeks after the antiviral therapy initiation liver enzymes were in normal ranges. One year after the start of antiviral treatment HBV DNA PCR test did not detect any viral particles. The patient is in complete remission of malignant disease, and still receiving therapy with lamivudine. HBV screening in cancer patients is necessary in order to provide a prompt antiviral therapy and to prevent postponement or even cessation of planned anticancer treatment. HBsAg positive patients should start prophylactic antiviral treatment before the start of immunosuppressive treatment. Chemotherapy protocols consisting rituximab and corticosteroids significantly increase the risk of reactivation. If reactivation is diagnosed in course of chemotherapy, the therapy should be stopped and antiviral treatment should be applied as soon as possible. Treatment with lamivudine is continued at least 6 months after the chemotherapy end.
乙型肝炎病毒(HBV)感染的自然过程取决于宿主的免疫状态。在癌症患者中，由于化疗和恶性疾病本身导致的免疫抑制，病毒复制潜力和宿主免疫反应之间的平衡被破坏，导致急性HBV感染或再激活。我们报告了一例HBsAg阳性，弥漫性大B细胞胃淋巴瘤CD20+期IB患者，接受6个周期的R-CHOP方案和2个周期的利妥昔单抗治疗。在抗癌治疗成功5个月后，患者出现慢性HBV感染再激活(肝酶、HBsAg+、IgM抗hbc +、HBeAg(-)和HBV DNA 5×10拷贝/ml增加10倍)。开始拉米夫定抗病毒治疗。抗病毒治疗开始4周后肝酶恢复正常。抗病毒治疗开始一年后，HBV DNA PCR检测未检出任何病毒颗粒。患者恶性疾病完全缓解，仍在接受拉米夫定治疗。为了及时提供抗病毒治疗，防止推迟甚至停止计划的抗癌治疗，对癌症患者进行HBV筛查是必要的。HBsAg阳性患者应在开始免疫抑制治疗前开始预防性抗病毒治疗。化疗方案包括利妥昔单抗和皮质类固醇显著增加再激活的风险。如果在化疗过程中被诊断为再激活，应尽快停止治疗并应用抗病毒治疗。拉米夫定治疗在化疗结束后至少持续6个月。
{"title":"Hepatitis B reactivation after therapy for non-Hodgkin lymphoma: A case report with review of literature","authors":"Gorana Matovina-Brko, Maja Ružić, M. Fabri, L. Popović, Ivana Kolarov-Bjelobrk, J. Trifunović","doi":"10.2298/aoo1304151m","DOIUrl":"https://doi.org/10.2298/aoo1304151m","url":null,"abstract":"The natural course of hepatitis B virus (HBV) infection depends on the immune status of the host. In cancer patients, as the consequence of immune suppression due to chemotherapy and malignant disease itself, the balance between replicative potential of the virus and immune response of the host is disrupted leading to acute HBV infection or reactivation. We present a case of HBsAg positive, diffuse large B cell gastric lymphoma patient CD20+ staged IB, treated with six cycles of R-CHOP protocol and two cycles with rituximab monotherapy. Five months after the successful anticancer treatment, patient developed reactivation of chronic HBV infection (ten-fold increase in liver enzymes, HBsAg+, IgM antiHBc+, HBeAg(-), and HBV DNA 5×10 copies/ml). Antiviral therapy with lamivudine was started. Four weeks after the antiviral therapy initiation liver enzymes were in normal ranges. One year after the start of antiviral treatment HBV DNA PCR test did not detect any viral particles. The patient is in complete remission of malignant disease, and still receiving therapy with lamivudine. HBV screening in cancer patients is necessary in order to provide a prompt antiviral therapy and to prevent postponement or even cessation of planned anticancer treatment. HBsAg positive patients should start prophylactic antiviral treatment before the start of immunosuppressive treatment. Chemotherapy protocols consisting rituximab and corticosteroids significantly increase the risk of reactivation. If reactivation is diagnosed in course of chemotherapy, the therapy should be stopped and antiviral treatment should be applied as soon as possible. Treatment with lamivudine is continued at least 6 months after the chemotherapy end.","PeriodicalId":35645,"journal":{"name":"Archive of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68402135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sunita K. Shere, Anjali S. Kulkarni, Shubhjyoti Pore, R. Bindu
Testicular fibroma of gonadal stromal origin is a rare benign tumor of testis, which usually presents as a slow growing testicular mass. Intratesticular fibroma of gonadal stromal origin, with or without minor sex cord elements, must be considered, analogous to similar tumors in ovary, as a benign tumor. Until now, only 25 cases of testicular fibroma have been reported in the literature. We reported a case of testicular fibroma in a 20 years male who presented with painless right testicular enlargement since two years. Ultrasonography (USG) showed heterogeneous mass in right scrotum suggestive of testicular malignancy. Right orchidectomy was done. Histopathological diagnosis was testicular fibroma, which was confirmed by immunohistochemistry.
{"title":"Testicular fibroma: A case report","authors":"Sunita K. Shere, Anjali S. Kulkarni, Shubhjyoti Pore, R. Bindu","doi":"10.2298/AOO1304139S","DOIUrl":"https://doi.org/10.2298/AOO1304139S","url":null,"abstract":"Testicular fibroma of gonadal stromal origin is a rare benign tumor of testis, which usually presents as a slow growing testicular mass. Intratesticular fibroma of gonadal stromal origin, with or without minor sex cord elements, must be considered, analogous to similar tumors in ovary, as a benign tumor. Until now, only 25 cases of testicular fibroma have been reported in the literature. We reported a case of testicular fibroma in a 20 years male who presented with painless right testicular enlargement since two years. Ultrasonography (USG) showed heterogeneous mass in right scrotum suggestive of testicular malignancy. Right orchidectomy was done. Histopathological diagnosis was testicular fibroma, which was confirmed by immunohistochemistry.","PeriodicalId":35645,"journal":{"name":"Archive of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68402517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hodgkin lymphoma and anaplastic large cell lymphoma are malignancies that highly express CD30 antigen on the cell surface. Both are generally curable by standard chemotherapy but refractory diseases and relapses are treatment problems. Brentuximab-vedotin is a labeled monoclonal antibody against CD30 and it is approved for the treatment of Hodgkin lymphoma relapsed after autologous stem cell transplantation and for relapsed anaplastic large cell lymphoma. This is the first drug approved for the treatment of Hodgkin lymphoma after 30 years.
{"title":"CD30 - the head of TNF-family… or a successful story of brentuximab vedotin","authors":"L. Popović, D. Jovanović, Ðordje Popovic","doi":"10.2298/AOO1301017P","DOIUrl":"https://doi.org/10.2298/AOO1301017P","url":null,"abstract":"Hodgkin lymphoma and anaplastic large cell lymphoma are malignancies that highly express CD30 antigen on the cell surface. Both are generally curable by standard chemotherapy but refractory diseases and relapses are treatment problems. Brentuximab-vedotin is a labeled monoclonal antibody against CD30 and it is approved for the treatment of Hodgkin lymphoma relapsed after autologous stem cell transplantation and for relapsed anaplastic large cell lymphoma. This is the first drug approved for the treatment of Hodgkin lymphoma after 30 years.","PeriodicalId":35645,"journal":{"name":"Archive of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2298/AOO1301017P","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68401703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：